<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Survival, quality of life, and late complications after hematopoietic cell transplantation in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Survival, quality of life, and late complications after hematopoietic cell transplantation in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Survival, quality of life, and late complications after hematopoietic cell transplantation in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nelson J Chao, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Negrin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1378588684"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hematopoietic cell transplantation (HCT) has the potential to cure leukemias, lymphomas, hemoglobinopathies, and other disorders, but transplantation is associated with high rates of complications and mortality. Complications and mortality are highest in the first year after HCT, due to drug toxicities and the intensity of immunosuppression, but generally decline with time. Late complications (ie, &gt;1 year after transplantation) can affect many organ systems, impair the quality of life (QoL), and increase mortality, but most patients can eventually return to work and experience near-normal QoL. </p><p>This topic will discuss survival, quality of life, and late complications after allogeneic and autologous HCT in adults.</p><p>Complications encountered in the first year after transplantation ("early complications"), clinical manifestations of acute and chronic graft-versus-host-disease, and second cancers after HCT are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3558.html" rel="external">"Secondary cancers after hematopoietic cell transplantation"</a>.)</p><p></p><p>Transplantation outcomes for specific diseases and in children are discussed separately in those topics.</p><p class="headingAnchor" id="H725335092"><span class="h1">OVERVIEW OF LATE COMPLICATIONS</span><span class="headingEndMark"> — </span>HCT is associated with high rates of complications and mortality. Complications and mortality are highest in the first year due to drug toxicities and the intensity of immunosuppression, but they generally decline over time. Most patients are eventually able to return to work and experience near-normal quality of life (QoL). Importantly, a healthy lifestyle and appropriate preventive care can attenuate the risk for adverse outcomes.</p><p class="headingAnchor" id="H226432400"><span class="h1">CONTRIBUTING FACTORS</span><span class="headingEndMark"> — </span>Outcomes and late complications with HCT are affected by the underlying illness, comorbid conditions, aspects of transplantation, and complications that arise in the first year after HCT:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Underlying illness</strong> – The underlying illness (eg, acute leukemia, hemoglobinopathy), prior treatment (eg, chemotherapy, radiation therapy), complications (eg, chemotherapy-associated cardiotoxicity, iron overload from multiple transfusions, recurrent infections), and disease status at the time of transplantation (eg, complete remission versus residual disease) affect survival, QoL, and the nature and severity of late complications. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspects of transplantation</strong> – Development and severity of late complications are influenced by the type of HCT conditioning regimen (eg, chemotherapy, radiation therapy), intensity of the regimen (eg, myeloablative, reduced intensity, nonmyeloablative), type of graft (eg, autologous versus allogeneic), and immunosuppressive regimen for graft-versus-host-disease (GVHD). (See <a class="local">'Survival after allogeneic HCT'</a> below and <a class="local">'Survival after autologous HCT'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbid conditions</strong> – Comorbid cardiovascular disease, diabetes mellitus, and pulmonary, hepatic, and renal conditions may exacerbate or reduce tolerance for late complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early complications after HCT</strong> – Early complications, including infections, cytopenias, and manifestations of acute and chronic GVHD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a>.) </p><p></p><p class="headingAnchor" id="H2429996700"><span class="h1">SURVIVAL</span><span class="headingEndMark"> — </span>The greatest risk of death in the first years after transplantation is recurrence of the underlying disease; other common causes of death include infection, second cancers, and organ system dysfunction. Survival is influenced by whether the patient underwent allogeneic or autologous HCT. </p><p class="headingAnchor" id="H1421755839"><span class="h2">Survival after allogeneic HCT</span><span class="headingEndMark"> — </span>Life expectancy after allogeneic HCT is lower than that of the general population. Causes of death vary with the time since transplantation, age, and the underlying illness and its prior treatment. (See  <a class="medical medical_review" href="/z/d/html/3558.html" rel="external">"Secondary cancers after hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a>.)</p><p>Overall survival (OS) after allogeneic HCT is lower than that of the general population for at least 10 to 30 years after transplantation [<a href="#rid1">1-9</a>]. Relapse of the underlying disease is the most common cause of death in the first four years after transplantation, but patients who are relapse-free beyond this point have a high probability of long-term survival [<a href="#rid10">10</a>]. The predominant causes of nonrelapse mortality (NRM) after allogeneic HCT are chronic graft-versus-host-disease (cGVHD), infection, second cancers, and organ system dysfunction. </p><p>Informative studies of survival after allogeneic HCT include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of more than 10,000 patients, 10-year OS was estimated to be 85 percent in those who remained relapse-free two years after myeloablative allogeneic HCT for acute leukemia, myelodysplastic syndrome, lymphoma, or severe aplastic anemia [<a href="#rid1">1</a>]. At two years, the mortality rate was higher than that of the general population, but the relative risk for death declined over time. Except for patients with lymphoma, the increased rate of death did not return to that of the general population during the median follow-up of nine years. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-institution study of 1479 individuals who survived ≥2 years after allogeneic HCT, 15-year OS was estimated to be 80 percent [<a href="#rid5">5</a>]. Compared to age-, sex-, and calendar year-matched general United States population, the standardized mortality ratio (SMR) was 9.9 (95% CI 8.7-11.2) and was highest in years 2 to 5 post-HCT (78-fold increase); mortality rates remained elevated for at least 15 years. Disease relapse (29 percent) was the most common cause of premature death; two-thirds of relapses occurred in years 2 to 5. The most common causes of NRM were cGVHD (22 percent), infection (11 percent), second cancers (7 percent), pulmonary complications (5 percent), cardiac toxicity (2 percent), and other treatment-related events (8 percent). Compared with patients without cGVHD, NRM was increased 2.7-fold for those with cGVHD. </p><p></p><p class="headingAnchor" id="H2821917960"><span class="h2">Survival after autologous HCT</span><span class="headingEndMark"> — </span>The mortality rate after autologous HCT remains elevated for decades, but it approaches that of the general population over time. Disease relapse is the most common cause of death in the earlier years after autologous HCT, but infections, organ dysfunction, and second cancers account for most later deaths. Unlike allogeneic HCT, patients who undergo autologous HCT do not experience graft-versus-host disease (GVHD).</p><p>Examples of outcomes after autologous HCT include:</p><p class="bulletIndent1"><span class="glyph">●</span>The estimated 20-year OS was 80 percent (95% CI 78-83 percent) in a single-institution study of 1672 patients who were relapse-free for ≥5 years [<a href="#rid2">2</a>]. Regardless of the patient's age, life expectancy was one-third lower than the general population, and mortality rates remained elevated four- to ninefold for at least three decades after transplantation. Leading causes of death were disease relapse, second cancers, infection, respiratory disease, and cardiovascular disease [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single-institution study of 309 patients who underwent autologous HCT for lymphoma reported that the overall mortality rate approached that of the general population over time, but it did not return to normal even after 15 years of follow-up [<a href="#rid11">11</a>]. NRM surpassed relapse as the main cause of death approximately eight years after transplantation. The most common causes of NRM were respiratory failure (31 percent), cardiac toxicity (15 percent), second cancers (15 percent), and infection (13 percent). In the first two years after HCT, respiratory failure and infection were the most common causes of NRM, but second cancers predominated in later years. </p><p></p><p class="headingAnchor" id="H2662332171"><span class="h1">QUALITY OF LIFE</span></p><p class="headingAnchor" id="H1693644391"><span class="h2">Key determinants of QoL</span><span class="headingEndMark"> — </span>Quality of life (QoL) is a multidimensional concept that includes the individual's perception of physical function, psychological state, independence, financial well-being, and social and sexual satisfaction. QoL is influenced by the individual's goals, expectations, cultural standards, and value systems. There is no consensus regarding the precise definition of QoL, its component parts, or the optimal assessment instruments. Health-related QoL and its assessment are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2833.html" rel="external">"Evaluation of health-related quality of life (HRQL) in patients with a serious life-threatening illness"</a>.)</p><p>Key determinants of QoL after HCT are discussed in the sections below. </p><p class="headingAnchor" id="H2934075451"><span class="h3">Physical function</span><span class="headingEndMark"> — </span>Physical function refers to the ability to conduct a variety of activities, ranging from self-care to more vigorous activities that require substantial ability, strength, or endurance [<a href="#rid12">12</a>]. Functional limitations and symptoms (especially fatigue) affect a significant proportion of long-term survivors, but most transplant survivors resume routine activities over time. The type of transplantation can affect physical function outcomes. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allogeneic HCT </strong>– Prior to allogeneic HCT, physical function is typically inferior to that of the general population (due to the underlying disease and its treatment) and a nadir for physical function is generally observed 30 to 100 days after transplantation [<a href="#rid13">13,14</a>]. A prospective study that included 61 patients reported that physical function one to five years after allogeneic HCT was comparable to that of the general population [<a href="#rid13">13</a>]. Other studies also documented functional improvement within one to four years after transplantation [<a href="#rid15">15-18</a>]. Factors associated with impaired recovery of physical function at one year include severe chronic graft-versus-host disease (cGVHD), pretransplant physical impairment, and family conflict [<a href="#rid14">14,19</a>]. </p><p></p><p class="bulletIndent1">Major functional limitations (eg, reduced mobility, impaired performance of usual activities), frequent doctor visits, or hospitalization in the previous year were reported by 18 to 34 percent of patients 1.5 to 5 years after transplantation [<a href="#rid20">20-22</a>]. The most common physical complaints at two years were sexual difficulties (36 percent), fatigue (33 percent), painful joints (20 percent), skin changes (16 percent), other pain (11 percent), and mouth sores (9 percent) [<a href="#rid23">23</a>]. Compared to individuals without cancer, allogeneic HCT survivors reported small to moderate physical impairments at 5 to 10 years post-transplant [<a href="#rid24">24-26</a>]. </p><p></p><p class="bulletIndent1">A multicenter study randomly assigned 105 patients undergoing allogeneic HCT to routine social contacts versus a partially supervised exercise program before, during, and up to eight weeks after hospital discharge [<a href="#rid27">27</a>]. Compared with control patients, those assigned to the exercise program had better ratings on measures of fatigue, physical fitness, and global distress.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous HCT</strong> – Patients generally experience a nadir of physical function between 10 days and 6 weeks after autologous HCT due to early toxicity (eg, nausea, vomiting, mucositis) associated with the conditioning regimen [<a href="#rid28">28-31</a>]. This impairment progressively improves and most patients match or exceed their baseline by three months, six months, and/or one year after transplantation [<a href="#rid12">12,28,30,32-34</a>]. A prospective study that included 69 patients who underwent autologous HCT reported that physical function was comparable to that of the general population after one to five years [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1">Fatigue is common before, during, and after autologous HCT, but rates vary with the underlying disease [<a href="#rid35">35-37</a>]. In one study, one year after autologous HCT, most patients reported good appetite, stable weight, and little difficulty sleeping [<a href="#rid32">32</a>]. However, three years after autologous HCT, approximately two-thirds of patients reported persistent difficulty with activities such as taking a long walk or carrying a shopping bag [<a href="#rid33">33</a>]. A prospective single-institution study reported that QoL was comparable in patients undergoing inpatient versus outpatient autologous HCT [<a href="#rid38">38</a>].</p><p></p><p class="headingAnchor" id="H2949640035"><span class="h3">Employment/financial</span><span class="headingEndMark"> — </span>The ability to return to employment, homemaking, or studies is referred to as role functioning. In general, rates of employment improve over time, but patients may experience denial of health or life insurance. Financial worries in transplant survivors are often underestimated by caregivers.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allogeneic HCT</strong> – Role functioning prior to allogeneic transplantation is lower than population norms due in part to the underlying illness and/or comorbid conditions; this is exacerbated by the prolonged hospitalization associated with allogeneic HCT. In general, most patients who survive relapse-free can expect to resume work, school, and other roles in the community.</p><p></p><p class="bulletIndent1">Role functioning is impaired in the first 100 days after transplant, but by one year it is typically comparable or slightly improved compared with baseline and continues to improve over time [<a href="#rid13">13,39-41</a>]. Between one and four years after transplantation, two-thirds to three-quarters of patients have returned to work or school [<a href="#rid5">5,18,21,23</a>]. For at least three years, survivors continue to have comparable or slightly impaired role function compared with individuals without cancer [<a href="#rid24">24,26,41,42</a>]. However, by 10 years, allogeneic HCT survivors did not differ from controls (ie, age-, race-, and sex-matched individuals without cancer) with regard to full-time employment [<a href="#rid43">43</a>]. Among all patients who were transplanted (including those who died or relapsed), 20 to 34 percent had returned to work between years 1 and 5 [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1">Compared with their siblings, long-term allogeneic transplant survivors are less likely to be married and more likely to have health-related issues preventing them from holding a job and difficulty maintaining health insurance or acquiring life insurance [<a href="#rid5">5,44-47</a>]. Reduced role functioning and a delayed return to work was more common in women and in patients with extensive cGVHD [<a href="#rid19">19,48,49</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous HCT</strong> – There are typically substantial deficits in role functioning in the pre- and peri-autologous HCT periods, but this improves rapidly [<a href="#rid32">32,33</a>]. At three years, transplant survivors still had deficits compared to a reference population and at five years half of patients reported limitations in work or household activities [<a href="#rid33">33,50</a>]. However, by 10 years, rates of employment were not different than age-, sex-, and race-matched non-HCT controls [<a href="#rid43">43</a>]. A systematic analysis reported that pretransplant psychological distress predicted a lower likelihood and/or delayed return to work [<a href="#rid51">51</a>]. </p><p></p><p class="headingAnchor" id="H3370942325"><span class="h3">Anxiety/depression</span><span class="headingEndMark"> — </span>Psychological distress (eg, anxiety, depression) is common before, during, and after HCT, but generally improves over time and approaches rates in the general population. Contributing factors include physical and cognitive effects of the underlying disease and its treatments, fear of relapse and death, a sense of isolation or stigmatization, and financial insecurity [<a href="#rid12">12</a>]. </p><p>Moderate to severe depressive symptoms were reported by 25 to 40 percent of patients in the first year after transplantation, but it is unclear if this differs from healthy control populations [<a href="#rid20">20,29,52,53</a>]. Several studies have reported that three or more years after transplantation, psychological distress is comparable to that of the normative population [<a href="#rid13">13,21,24,43</a>]. A single-institution study of 84 patients reported that depressive symptoms declined, QoL improved, and patients drank less alcohol over time [<a href="#rid54">54</a>]. However, other studies have reported that emotional functioning was impaired relative to healthy controls 5 to 10 years after HCT [<a href="#rid25">25,26,43,55</a>]. A European study reported that transplant survivors had higher rates of suicide and accidental death than the general population [<a href="#rid56">56</a>]. </p><p>A systematic analysis reported that depression after transplantation was associated with psychological distress prior to HCT and female sex [<a href="#rid51">51</a>]. Psychological distress may be exacerbated by cGVHD, but it can occur after allogeneic HCT even without cGVHD [<a href="#rid25">25,44,57</a>]. Other studies reported that distress was associated with lower socioeconomic status, lower income, lack of employment, and unmarried status [<a href="#rid58">58,59</a>]. Older patients were not more compromised than younger ones [<a href="#rid29">29</a>]. </p><p>A variety of psychological interventions have been examined in patients undergoing transplantation. Although small to medium effects have been reported, there is no consensus regarding the most effective strategies for relieving psychological distress after HCT [<a href="#rid60">60-62</a>].</p><p class="headingAnchor" id="H438802612"><span class="h3">Social/sexual well-being</span><span class="headingEndMark"> — </span>Social well-being refers to participation in routine social activities, receipt of support, feelings of closeness, and perceived communication with a partner and other loved ones.</p><p>One study reported that marital satisfaction six months after HCT did not differ from pretransplantation satisfaction [<a href="#rid53">53</a>]. One study found that social impairment lessened over the first year after either allogeneic or autologous HCT and became comparable to population norms [<a href="#rid13">13</a>]. In another study, compared to allogeneic recipients, a higher percentage of patients who underwent autologous HCT enjoyed socializing with relatives and friends during the first year, but this difference did not persist after 12 and 24 months [<a href="#rid23">23</a>]. Among allogeneic survivors, general social participation was below population norms from baseline until 12 months after transplantation [<a href="#rid16">16</a>]. Social well-being did not differ from population norms after 10 years beyond allogeneic HCT [<a href="#rid24">24,43</a>].</p><p>HCT can affect sexual function, satisfaction, and intimacy [<a href="#rid53">53,63,64</a>]. Patients' concerns include decreased libido, fatigue, infertility, erectile/ejaculatory dysfunction, premature menopause, dyspareunia, and vaginal dryness, narrowing, or fibrosis. Changes in body image, anxiety, depression, and worries about disease recurrence may also contribute to sexual dysfunction/satisfaction. Despite the prevalence of sexual dysfunction, about half of patients report that their health care provider did not discuss potential effects on sexuality prior to HCT and had not discussed them in follow-up visits at one and three years after transplantation [<a href="#rid65">65</a>].</p><p>Further discussion of sexual dysfunction in female cancer survivors is presented separately. (See  <a class="medical medical_review" href="/z/d/html/17009.html" rel="external">"Overview of sexual dysfunction in female cancer survivors"</a>.)</p><p class="headingAnchor" id="H2100357831"><span class="h1">EARLY COMPLICATIONS</span><span class="headingEndMark"> — </span>Early complications refer to conditions that are manifest in the first year after transplantation and are described separately. (See  <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H1743440140"><span class="h1">LATE COMPLICATIONS</span></p><p class="headingAnchor" id="H887066688"><span class="h2">Overview of late complications</span><span class="headingEndMark"> — </span>Late complications are those that are manifest beyond one year after transplantation. Some late complications (eg, chronic graft-versus-host disease [cGVHD]) may have begun earlier, while others (eg, second cancers) are first noted years after transplantation. Some late complications (eg, cardiovascular events, bronchiolitis obliterans, end-stage renal failure) contribute to nonrelapse mortality (NRM), while others (eg, dry eyes, xerostomia, avascular necrosis) may be a source of substantial morbidity and impaired quality of life (QoL), but do not reduce overall survival (OS) [<a href="#rid10">10,66,67</a>].</p><p>Most transplant survivors experience at least one late complication of HCT. In a large single-institution study, the cumulative incidence after five years of any nonmalignant late effect was 45 percent after autologous HCT and 79 percent after allogeneic HCT; 3 and 26 percent, respectively, experienced ≥3 late effects [<a href="#rid68">68</a>]. In a study with median follow-up of seven years, nearly 1800 adult survivors of allogeneic HCT had higher rates of hospitalization and all-cause mortality than other cancer survivors or the general population [<a href="#rid9">9</a>]. In that study, transplant survivors had more hospitalizations or deaths with infections, more respiratory complications, and increased risk for digestive, skin, and musculoskeletal complications compared with non-HCT cancer survivors; rates of circulatory complications and second cancers were similar.</p><p class="headingAnchor" id="H3311042734"><span class="h2">Infectious diseases</span><span class="headingEndMark"> — </span>Infections are a common cause of morbidity and NRM following HCT. An overview of infections after HCT is provided separately. (See  <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a>.)</p><p>Immune reconstitution typically requires 12 to 18 months and, consequently, the risk of infection is highest in the first two years. However, an increased risk for infections may be present for years and is influenced by the type of transplantation, immunosuppressive agents used, and the presence of other transplant-related complications. </p><p>Important considerations regarding infections after transplantation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune reconstitution is slower after allogeneic HCT and is especially prolonged in recipients of human leukocyte antigen (HLA)-mismatched grafts, T cell-depleted grafts, and in the presence of cGVHD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HCT recipients typically lose immunity to pathogens against which they were previously immunized. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Latent viral infections may be reactivated, and new viral infections acquired through blood transfusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asplenia, whether surgical or functional (eg, in association with cGVHD) increases the risk of infections by encapsulated bacteria (eg, <em>Streptococcus pneumoniae, Haemophilus influenzae, Neisseria</em> spp, <em>Capnocytophaga canimorsus</em>) and by intra-erythrocytic parasites (eg, <em>Babesia microti</em>) in certain geographic areas. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical presentations that suggest an infection may also be caused by cGVHD, lung irradiation, disease recurrence, second cancers, or other noninfectious etiologies.</p><p></p><p class="headingAnchor" id="H132846787"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>Cardiovascular (CV) diseases are among the most common causes of morbidity and NRM in transplant survivors. Rates of CV complications vary with prior treatments, traditional CV risk factors (eg, hypertension, dyslipidemia, diabetes), and the presence of cGVHD. </p><p>The prevalence of long-term CV complications in transplantation survivors is approximately 5 percent at 5 years and 9 percent at 15 years [<a href="#rid69">69-71</a>]. CV diseases account for 2 to 11 percent of mortality among long-term transplant survivors [<a href="#rid2">2,5,6</a>]. As an example, in a single-institution study, cardiomyopathy, ischemic heart disease, all-cause CV death, and stroke were reported in 6.0, 3.8, 3.7, and 3.5 percent of survivors, respectively, at 10 years [<a href="#rid72">72</a>]. Most cases of heart failure (HF) occur within the first four years after transplantation, but HF may also present more than eight years after HCT [<a href="#rid73">73</a>]. In one study, the incidence of CV death was greater in transplant survivors than in a matched nontransplant population, while another study reported that survivors of HCT have a higher incidence of CV conditions compared with their nontransplant siblings [<a href="#rid3">3,74</a>]. </p><p>Factors associated with increased CV risk in transplant survivors include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased incidence of CV risk factors</strong> – The risk for developing CV risk factors (eg, hypertension, dyslipidemia, diabetes, metabolic syndrome) is greater in transplant survivors than in the general population. A single-center retrospective study estimated the 10-year cumulative incidences of new-onset hypertension, diabetes, and dyslipidemia were 22, 10, and 31 percent, respectively, among 1885 HCT survivors who were followed for a median of 5.9 years [<a href="#rid75">75</a>]. Compared with autologous HCT, allogeneic HCT was associated with earlier development of CV risk factors and an increased likelihood of developing multiple risk factors. </p><p></p><p class="bulletIndent1">One study that included both allogeneic and autologous transplantation reported that prior smoking, hypertension, dyslipidemia, diabetes, and obesity conferred additional risk for all CV outcomes (hazard ratio [HR] ≥1.5 for each additional risk factor), except for stroke [<a href="#rid72">72</a>]. In another study, modifiable risk factors including smoking, obesity, low physical activity, and a diet low in fruits and vegetables were associated with increased CV disease in transplant survivors, but healthier lifestyles attenuated the risk [<a href="#rid76">76</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic GVHD </strong>– Active cGVHD and its treatment are associated with increased CV risk. In one study, compared with patients without active cGVHD, CV mortality was greater in patients with active cGVHD (HR 4.0; 95% CI 1.1-14.7) [<a href="#rid72">72</a>]. Treatments for cGVHD, including <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, and glucocorticoids are associated with hypertension and may exacerbate hyperlipidemia [<a href="#rid69">69,77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior cancer treatment: </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemotherapy</strong> – Prior chemotherapy, including anthracyclines and high dose <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, can lead to delayed nonischemic HF. (See  <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"</a> and  <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Radiation</strong> – Chest radiation prior to HCT or total body irradiation (TBI) as a component of the conditioning regimen are associated with accelerated atherosclerosis and other forms of cardiotoxicity [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonal hematopoiesis of indeterminate potential (CHIP)</strong> – CHIP is associated with increased mortality from CV complications. CHIP is associated with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which are common indications for HCT, and CHIP may persist even after successful treatment of a hematopoietic neoplasm. CHIP and its association with CV complications are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/107866.html" rel="external">"Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis"</a>.) </p><p></p><p>CV disease in cancer survivors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/17017.html" rel="external">"Cancer survivorship: Cardiovascular and respiratory issues"</a>.)</p><p>Surveillance for CV disease in transplant survivors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Cardiovascular'</a>.)</p><p class="headingAnchor" id="H2690168367"><span class="h2">Pulmonary disease</span><span class="headingEndMark"> — </span>Late noninfectious pulmonary complications include chronic lung allograft dysfunction (CLAD) and its two main phenotypes, CLAD-bronchiolitis obliterans syndrome and CLAD-restrictive allograft syndrome, which are manifestations of cGVHD of the lung; pulmonary hypertension; and other disorders.<strong> </strong></p><p>Although chronic respiratory failure is more common after allogeneic HCT than autologous HCT, pulmonary complications are the most common cause of late NRM after autologous HCT [<a href="#rid5">5,11</a>]. Factors that contribute to respiratory conditions include lung injury from TBI, chemotherapy (eg, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>), infections, and inflammatory pneumonitides. Pulmonary complications after autologous and allogeneic HCT and pulmonary manifestations of cGVHD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4342.html" rel="external">"Pulmonary complications after autologous hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"</a> and  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Lung'</a>.)</p><p>Monitoring the long-term survivor for pulmonary complications is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Pulmonary'</a>.)</p><p class="headingAnchor" id="H409663582"><span class="h2">Liver disease</span><span class="headingEndMark"> — </span>Long-term survivors of HCT are at risk for liver dysfunction due to multiple contributing factors, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic GVHD </strong>– Clinical effects of cGVHD on the liver are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Liver'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Medications are a common cause of liver abnormalities. (See  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral hepatitis</strong> – Patients with a history of infection with hepatitis B virus and hepatitis C virus (if not previously treated) are at risk for the reactivation of latent hepatitis and liver failure. (See  <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/3672.html" rel="external">"Clinical manifestations and natural history of chronic hepatitis C virus infection", section on 'Liver histology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron overload</strong> – Iron overload is rare after autologous HCT but has been reported in 25 to 60 percent of patients after allogeneic HCT [<a href="#rid79">79-81</a>]. Chronic transfusional support may cause iron overload and secondary hemochromatosis, with the potential for long-term hepatic, pancreatic, gonadal, infectious, and cardiac complications [<a href="#rid82">82,83</a>]. Approximately one-third of long-term allogeneic HCT survivors have evidence of iron overload [<a href="#rid79">79</a>]. Evaluation and management of iron overload is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload"</a> and  <a class="medical medical_review" href="/z/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects"</a>.)</p><p></p><p>Monitoring liver function in the transplant survivor is described separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Liver disease'</a>.) </p><p class="headingAnchor" id="H3563648543"><span class="h2">Renal dysfunction</span><span class="headingEndMark"> — </span>Transplant survivors have increased rates of kidney disease, including thrombotic microangiography, drug toxicity (eg, calcineurin inhibitors), nephrotic syndrome, and membranous glomerulopathy, but estimates of the prevalence of renal dysfunction vary widely [<a href="#rid84">84-86</a>]. Risk factors for renal complications after transplantation include prior kidney disease, radiation injury, and calcineurin inhibitors (which may exacerbate hypertension and microangiopathy). Renal complications of HCT are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation"</a>.)</p><p>Monitoring kidney function in the transplant survivor is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Health maintenance'</a>.)</p><p class="headingAnchor" id="H2686931327"><span class="h2">Endocrine disorders</span><span class="headingEndMark"> — </span>Endocrine complications of HCT include:</p><p class="headingAnchor" id="H3403552594"><span class="h3">Diabetes/metabolic syndrome</span><span class="headingEndMark"> — </span>The risk for diabetes and metabolic syndrome varies with the type of HCT:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allogeneic HCT</strong> – The prevalence of diabetes is increased three- to fourfold after allogeneic HCT; risk factors include treatment with glucocorticoids and calcineurin inhibitors for the management of cGVHD [<a href="#rid87">87</a>]. A cohort analysis reported diabetes in 30 percent of patients two years after allogeneic HCT [<a href="#rid69">69</a>]. The association of diabetes with hyperlipidemia and hypertension ("metabolic syndrome") is common after transplantation since the individual components of this syndrome share several common risk factors [<a href="#rid88">88,89</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous HCT</strong> – The prevalence of diabetes is generally not increased after autologous HCT [<a href="#rid68">68,87</a>]. </p><p></p><p>Monitoring for diabetes and metabolic syndrome in transplant survivors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Diabetes/metabolic syndrome'</a>.)</p><p class="headingAnchor" id="H3420886337"><span class="h3">Hypothyroidism</span><span class="headingEndMark"> — </span>Hypothyroidism is common after transplantation and has been reported in nearly one-third of patients by 25 years after HCT [<a href="#rid90">90</a>]. Clinical hypothyroidism can be caused by chemotherapy preparative regimens, but the incidence is much higher for regimens that include TBI [<a href="#rid86">86</a>]. In one study, the incidence of clinical hypothyroidism in patients who underwent allogeneic HCT was approximately double that of sibling controls [<a href="#rid91">91</a>]. </p><p>Monitoring for hypothyroidism in transplant survivors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Other endocrine'</a>.)</p><p class="headingAnchor" id="H1218864610"><span class="h3">Hypogonadism and fertility issues</span><span class="headingEndMark"> — </span>Temporary or permanent hypogonadism is common after autologous and allogeneic transplantation due to active cGVHD and/or the conditioning regimen (eg, chemotherapy and/or TBI) [<a href="#rid92">92-96</a>]. Myeloablative allogeneic transplantation almost always causes permanent sterility. Changes in hormone levels may be accompanied by a loss of libido, erectile dysfunction, vaginal dryness, and dyspareunia. Causes of hypogonadism and infertility in association with HCT are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a> and  <a class="medical medical_review" href="/z/d/html/4801.html" rel="external">"Overview of infertility and pregnancy outcome in cancer survivors"</a> and  <a class="medical medical_review" href="/z/d/html/5464.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">"Cutaneous manifestations of graft-versus-host disease (GVHD)", section on 'Ocular and genital mucosa'</a>.)</p><p>One study reported that only four men and no women among 120 survivors of myeloablative HCT successfully conceived within 10 years of HCT [<a href="#rid97">97</a>]. Compared with 120 matched nontransplant sibling or friend controls, HCT survivors were more likely to have tried unsuccessfully to have children (12 versus 7 percent) and were more likely to investigate alternative family-building options because of infertility (22 versus 9 percent). Approximately one-half of transplant survivors &lt;40 years old expressed concerns regarding their infertility. </p><p>Effects of HCT on sexual well-being is discussed above. (See <a class="local">'Social/sexual well-being'</a> above.)</p><p>Evaluation and management of hypogonadism and fertility in the transplant survivor are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Other endocrine'</a>.)</p><p class="headingAnchor" id="H2124258667"><span class="h3">Hypoadrenalism</span><span class="headingEndMark"> — </span>Adrenal insufficiency<strong> </strong>has been reported in 13 percent of patients after allogeneic HCT and 1 percent of patients after autologous HCT [<a href="#rid68">68</a>]. Chronic administration of glucocorticoids for treatment of cGVHD can suppress the hypothalamic-pituitary-adrenal function and result in adrenal insufficiency. Cautions regarding management of hypoadrenalism in the transplant survivor are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Other endocrine'</a>.) </p><p class="headingAnchor" id="H1882897972"><span class="h2">Bone and joints</span><span class="headingEndMark"> — </span>Late complications affecting bone include osteopenia, osteoporosis, and avascular necrosis. Patients with cGVHD are also at risk for glucocorticoid-induced myopathy, sclerotic changes in the skin and fascia that can limit joint mobility, osteopenia, and avascular necrosis of the hip or other joints [<a href="#rid86">86,98-100</a>]. (See  <a class="medical medical_review" href="/z/d/html/5171.html" rel="external">"Glucocorticoid-induced myopathy"</a> and  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">"Cutaneous manifestations of graft-versus-host disease (GVHD)", section on 'Sclerotic manifestations'</a>.)</p><p>Accelerated bone loss occurs after both autologous and allogeneic HCT, and osteoporosis has been reported in up to half of transplant survivors [<a href="#rid101">101-105</a>]. Bone loss can be due to impaired calcium and vitamin D homeostasis, osteoblast and osteoclast dysfunction, hypogonadism, and post-transplant glucocorticoids (eg, in the conditioning regimen or for cGVHD) [<a href="#rid106">106</a>]. Vertebral, but not femoral, bone loss was reported to improve, at least partially, after HCT, even without specific treatment [<a href="#rid107">107,108</a>]. In one trial, 99 adults undergoing allogeneic HCT were randomly assigned to receive calcium, vitamin D, and hormone therapy, with or without six infusions of <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a> (before and up to nine months after HCT) [<a href="#rid109">109</a>]. Patients who received pamidronate sustained less bone loss and had a trend towards fewer vertebral fractures. In a small randomized trial, <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> given immediately prior to and following allogeneic HCT was associated with improved bone mineral density at the femoral neck, in comparison with a control cohort [<a href="#rid110">110</a>]. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Bone and muscle effects'</a>.)</p><p>Avascular necrosis of a major joint has been reported in 4 to 19 percent of long-term survivors of HCT [<a href="#rid86">86,98,107,111</a>].<strong> </strong>Risk factors include prolonged glucocorticoid use, male sex, and exposure to TBI [<a href="#rid107">107</a>]. Hips (80 percent), knees (10 percent), wrists, and ankles are the most commonly involved joints. </p><p>Management of bone and joint complications in the transplant survivor is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Health maintenance'</a>.)</p><p class="headingAnchor" id="H1474335350"><span class="h2">Dermatologic disorders</span><span class="headingEndMark"> — </span>Skin is the organ that is most often involved in cGVHD. All transplant survivors are at increased risk for development of premalignant and malignant skin neoplasms [<a href="#rid86">86,98,112</a>]. </p><p>Evaluation of cutaneous graft-versus-host disease (GVHD) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">"Cutaneous manifestations of graft-versus-host disease (GVHD)"</a>.)</p><p>Other aspects of monitoring dermatologic complications of transplantation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Dermatologic'</a>.)</p><p class="headingAnchor" id="H3477853152"><span class="h2">Oral health</span><span class="headingEndMark"> — </span>Oral and dental complications are common after transplantation.</p><p>Chronic xerostomia (dry mouth) may be associated with prior chemotherapy, radiation therapy (eg, TBI in the preparative regimen, focal irradiation for lymphomas), mucosal or salivary gland cGVHD, and sclerodermatous cGVHD involving the oral aperture. All of these conditions can cause difficulty with chewing and swallowing and result in chronic malnutrition. Chronic xerostomia is also associated with accelerated dental caries, particularly along the gum line and between teeth [<a href="#rid113">113,114</a>].</p><p>Long-term survivors of allogeneic HCT have a sevenfold increased risk of developing oral cancer [<a href="#rid115">115</a>]. Persons who underwent HCT in their childhood may have additional complications with their teeth, including damaged enamel, permanent discoloration, and abnormal tooth development [<a href="#rid86">86</a>]. Squamous cell oral cancers are particularly common among patients who underwent HCT for Fanconi anemia [<a href="#rid86">86</a>].</p><p>Oral cGVHD and monitoring for oral complications of transplantation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Mucocutaneous'</a> and  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Oral health'</a>.)</p><p class="headingAnchor" id="H3038836081"><span class="h2">Ocular complications</span><span class="headingEndMark"> — </span>The most common ocular complications of HCT are cataracts and chronic dry eye (keratoconjunctivitis sicca) [<a href="#rid116">116-119</a>]. Transplant-associated conditions involving the anterior and posterior chambers of the eye include uveitis, choroiditis, infectious retinitis, and retinal microvascular disease.</p><p class="bulletIndent1"><span class="glyph">●</span>Cataracts develop in nearly all patients who receive TBI in their preparative regimen [<a href="#rid113">113</a>]. There may also be an increased incidence of cataracts after non-TBI regimens, especially for those who underwent transplantation as a child [<a href="#rid120">120</a>]. (See  <a class="medical medical_review" href="/z/d/html/6904.html" rel="external">"Cataract in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Keratoconjunctivitis sicca is especially common in association with decreased lacrimal gland function due to cGVHD and TBI. The incidence has been reported in approximately 20 percent of patients 15 years after allogeneic HCT and may be as high as 40 percent among patients with cGVHD [<a href="#rid86">86,98</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ischemic microvascular retinopathy (which may be manifest as cotton-wool spots or optic disc edema with or without a decrease in visual acuity) can complicate allogeneic HCT, especially in patients receiving <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> for cGVHD [<a href="#rid86">86</a>]. </p><p></p><p>Monitoring for ocular complications in the transplant survivor is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Ocular complications'</a>.)</p><p class="headingAnchor" id="H2237264933"><span class="h2">Neurocognitive health</span><span class="headingEndMark"> — </span>Neurocognitive impairment may occur in transplant survivors [<a href="#rid121">121,122</a>]. Risk factors for neurocognitive impairment include transplantation in childhood, allogeneic HCT, prolonged treatment with calcineurin inhibitors, exposure to TBI, cranial irradiation, and a history of intrathecal chemotherapy [<a href="#rid86">86,98,123,124</a>]. </p><p>Screening for neurologic findings after transplantation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Neurocognitive'</a>.)</p><p>Anxiety and depression in transplant survivors are discussed above. (See <a class="local">'Anxiety/depression'</a> above.)</p><p class="headingAnchor" id="H2150630971"><span class="h2">Second cancers</span><span class="headingEndMark"> — </span>Development of second cancers after transplantation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3558.html" rel="external">"Secondary cancers after hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H3143605488"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15854.html" rel="external">"Patient education: Autologous bone marrow transplant (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/117867.html" rel="external">"Patient education: Allogeneic bone marrow transplant (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the basics topics (see  <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3682226833"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Hematopoietic cell transplantation (HCT) can cure a variety of malignant and nonmalignant disorders, but it is associated with substantial toxicity. Even patients who are cured of their underlying disease may not achieve full restoration of health after HCT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survival</strong> – The most common cause of death in transplant survivors is recurrence of the underlying disease. (See <a class="local">'Survival'</a> above.)</p><p></p><p class="bulletIndent1">Causes of nonrelapse mortality include infection, second cancers, and organ system dysfunction. Survival patterns after transplantation are influenced by whether the patient undergoes allogeneic or autologous HCT and the underlying disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early complications</strong> – Early complications of HCT, which are manifest in the first year after transplantation, are described separately. (See  <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late complications</strong> – Late complications of HCT (ie, conditions encountered more than one year after transplantation) can affect nearly any organ system. (See <a class="local">'Late complications'</a> above.)</p><p></p><p class="bulletIndent1">Factors that contribute to late complications after HCT include the underlying illness, comorbid medical conditions, aspects of the transplantation, and early complications. (See <a class="local">'Contributing factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quality of life</strong> – Quality of life is a multidimensional concept that includes the individual's perception of function, independence and financial well-being, psychological state, and social and sexual satisfaction. Most transplant survivors resume routine activities over time, but functional limitations and symptoms (especially fatigue) affect a significant proportion of long-term survivors. (See <a class="local">'Quality of life'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29:2230.</a></li><li><a class="nounderline abstract_t">Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28:1011.</a></li><li><a class="nounderline abstract_t">Sun CL, Francisco L, Kawashima T, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010; 116:3129.</a></li><li><a class="nounderline abstract_t">Nivison-Smith I, Simpson JM, Dodds AJ, et al. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates. Biol Blood Marrow Transplant 2009; 15:1323.</a></li><li><a class="nounderline abstract_t">Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110:3784.</a></li><li><a class="nounderline abstract_t">Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105:4215.</a></li><li><a class="nounderline abstract_t">Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010; 28:1888.</a></li><li><a class="nounderline abstract_t">Majhail NS, Bajorunaite R, Lazarus HM, et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol 2009; 147:129.</a></li><li><a class="nounderline abstract_t">Chow EJ, Cushing-Haugen KL, Cheng GS, et al. Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors. J Clin Oncol 2017; 35:306.</a></li><li><a class="nounderline abstract_t">Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 2017; 10:220.</a></li><li><a class="nounderline abstract_t">Hill BT, Rybicki L, Bolwell BJ, et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br J Haematol 2011; 152:561.</a></li><li><a class="nounderline abstract_t">Mosher CE, Redd WH, Rini CM, et al. Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature. Psychooncology 2009; 18:113.</a></li><li><a class="nounderline abstract_t">Hjermstad MJ, Knobel H, Brinch L, et al. A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant 2004; 34:257.</a></li><li><a class="nounderline abstract_t">Syrjala KL, Chapko MK, Vitaliano PP, et al. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant 1993; 11:319.</a></li><li><a class="nounderline abstract_t">Lee SJ, Joffe S, Kim HT, et al. Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood 2004; 104:2194.</a></li><li><a class="nounderline abstract_t">Goetzmann L, Klaghofer R, Wagner-Huber R, et al. Quality of life and psychosocial situation before and after a lung, liver or an allogeneic bone marrow transplant. Swiss Med Wkly 2006; 136:281.</a></li><li><a class="nounderline abstract_t">Bevans MF, Marden S, Leidy NK, et al. Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38:101.</a></li><li><a class="nounderline abstract_t">Bush NE, Donaldson GW, Haberman MH, et al. Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients. Biol Blood Marrow Transplant 2000; 6:576.</a></li><li><a class="nounderline abstract_t">Worel N, Biener D, Kalhs P, et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant 2002; 30:619.</a></li><li><a class="nounderline abstract_t">Conner-Spady BL, Cumming C, Nabholtz JM, et al. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 2005; 36:251.</a></li><li><a class="nounderline abstract_t">Syrjala KL, Langer SL, Abrams JR, et al. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA 2004; 291:2335.</a></li><li><a class="nounderline abstract_t">Wolcott DL, Wellisch DK, Fawzy FI, Landsverk J. Adaptation of adult bone marrow transplant recipient long-term survivors. Transplantation 1986; 41:478.</a></li><li><a class="nounderline abstract_t">Lee SJ, Fairclough D, Parsons SK, et al. Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol 2001; 19:242.</a></li><li><a class="nounderline abstract_t">Kiss TL, Abdolell M, Jamal N, et al. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 2002; 20:2334.</a></li><li><a class="nounderline abstract_t">Andrykowski MA, Bishop MM, Hahn EA, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol 2005; 23:599.</a></li><li><a class="nounderline abstract_t">Kopp M, Holzner B, Meraner V, et al. Quality of life in adult hematopoietic cell transplant patients at least 5 yr after treatment: a comparison with healthy controls. Eur J Haematol 2005; 74:304.</a></li><li><a class="nounderline abstract_t">Wiskemann J, Dreger P, Schwerdtfeger R, et al. Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation. Blood 2011; 117:2604.</a></li><li><a class="nounderline abstract_t">Schulmeister L, Quiett K, Mayer K. Quality of life, quality of care, and patient satisfaction: perceptions of patients undergoing outpatient autologous stem cell transplantation. Oncol Nurs Forum 2005; 32:57.</a></li><li><a class="nounderline abstract_t">Sherman AC, Simonton S, Latif U, et al. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:12.</a></li><li><a class="nounderline abstract_t">van Agthoven M, Vellenga E, Fibbe WE, et al. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial. Eur J Cancer 2001; 37:1781.</a></li><li><a class="nounderline abstract_t">Vellenga E, van Agthoven M, Croockewit AJ, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001; 114:319.</a></li><li><a class="nounderline abstract_t">Chao NJ, Tierney DK, Bloom JR, et al. Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood 1992; 80:825.</a></li><li><a class="nounderline abstract_t">Gulbrandsen N, Hjermstad MJ, Wisløff F, Nordic Myeloma Study Group. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004; 72:172.</a></li><li><a class="nounderline abstract_t">Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol 2010; 148:373.</a></li><li><a class="nounderline abstract_t">Anderson KO, Giralt SA, Mendoza TR, et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 2007; 39:759.</a></li><li><a class="nounderline abstract_t">El-Banna MM, Berger AM, Farr L, et al. Fatigue and depression in patients with lymphoma undergoing autologous peripheral blood stem cell transplantation. Oncol Nurs Forum 2004; 31:937.</a></li><li><a class="nounderline abstract_t">Prieto JM, Blanch J, Atala J, et al. Clinical factors associated with fatigue in haematologic cancer patients receiving stem-cell transplantation. Eur J Cancer 2006; 42:1749.</a></li><li><a class="nounderline abstract_t">Martino M, Ciavarella S, De Summa S, et al. A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Biol Blood Marrow Transplant 2018; 24:608.</a></li><li><a class="nounderline abstract_t">Schulz-Kindermann F, Mehnert A, Scherwath A, et al. Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 39:789.</a></li><li><a class="nounderline abstract_t">Syrjala KL, Cummings C, Donaldson GW. Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial. Pain 1992; 48:137.</a></li><li><a class="nounderline abstract_t">Sutherland HJ, Fyles GM, Adams G, et al. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant 1997; 19:1129.</a></li><li><a class="nounderline abstract_t">Hayden PJ, Keogh F, Ni Conghaile M, et al. A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase. Bone Marrow Transplant 2004; 34:545.</a></li><li><a class="nounderline abstract_t">Syrjala KL, Langer SL, Abrams JR, et al. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 2005; 23:6596.</a></li><li><a class="nounderline abstract_t">Rusiewicz A, DuHamel KN, Burkhalter J, et al. Psychological distress in long-term survivors of hematopoietic stem cell transplantation. Psychooncology 2008; 17:329.</a></li><li><a class="nounderline abstract_t">Bishop MM, Beaumont JL, Hahn EA, et al. Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls. J Clin Oncol 2007; 25:1403.</a></li><li><a class="nounderline abstract_t">Wong FL, Francisco L, Togawa K, et al. Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns. Blood 2010; 115:2508.</a></li><li><a class="nounderline abstract_t">Sun CL, Francisco L, Baker KS, et al. Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood 2011; 118:4723.</a></li><li><a class="nounderline abstract_t">Chiodi S, Spinelli S, Ravera G, et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000; 110:614.</a></li><li><a class="nounderline abstract_t">Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006; 108:2867.</a></li><li><a class="nounderline abstract_t">Byar KL, Eilers JE, Nuss SL. Quality of life 5 or more years post-autologous hematopoietic stem cell transplant. Cancer Nurs 2005; 28:148.</a></li><li><a class="nounderline abstract_t">Braamse AM, Gerrits MM, van Meijel B, et al. Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies. Bone Marrow Transplant 2012; 47:757.</a></li><li><a class="nounderline abstract_t">Hjermstad MJ, Loge JH, Evensen SA, et al. The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation. Bone Marrow Transplant 1999; 24:1219.</a></li><li><a class="nounderline abstract_t">Langer S, Abrams J, Syrjala K. Caregiver and patient marital satisfaction and affect following hematopoietic stem cell transplantation: a prospective, longitudinal investigation. Psychooncology 2003; 12:239.</a></li><li><a class="nounderline abstract_t">Chang G, Orav EJ, McNamara TK, et al. Psychosocial function after hematopoietic stem cell transplantation. Psychosomatics 2005; 46:34.</a></li><li><a class="nounderline abstract_t">Hjermstad M, Holte H, Evensen S, et al. Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant 1999; 24:911.</a></li><li><a class="nounderline abstract_t">Tichelli A, Labopin M, Rovó A, et al. Increase of suicide and accidental death after hematopoietic stem cell transplantation: a cohort study on behalf of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Cancer 2013; 119:2012.</a></li><li><a class="nounderline abstract_t">Loberiza FR Jr, Rizzo JD, Bredeson CN, et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 2002; 20:2118.</a></li><li><a class="nounderline abstract_t">Knight JM, Syrjala KL, Majhail NS, et al. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biol Blood Marrow Transplant 2016; 22:2256.</a></li><li><a class="nounderline abstract_t">Kiserud CE, Fagerli UM, Smeland KB, et al. Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation. Acta Oncol 2016; 55:547.</a></li><li><a class="nounderline abstract_t">Faller H, Schuler M, Richard M, et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol 2013; 31:782.</a></li><li><a class="nounderline abstract_t">David N, Schlenker P, Prudlo U, Larbig W. Internet-based program for coping with cancer: a randomized controlled trial with hematologic cancer patients. Psychooncology 2013; 22:1064.</a></li><li><a class="nounderline abstract_t">McCabe C, Roche D, Hegarty F, McCann S. 'Open Window': a randomized trial of the effect of new media art using a virtual window on quality of life in patients' experiencing stem cell transplantation. Psychooncology 2013; 22:330.</a></li><li><a class="nounderline abstract_t">Tierney DK. Sexuality following hematopoietic cell transplantation. Clin J Oncol Nurs 2004; 8:43.</a></li><li><a class="nounderline abstract_t">Li Z, Mewawalla P, Stratton P, et al. Sexual health in hematopoietic stem cell transplant recipients. Cancer 2015; 121:4124.</a></li><li><a class="nounderline abstract_t">Humphreys CT, Tallman B, Altmaier EM, Barnette V. Sexual functioning in patients undergoing bone marrow transplantation: a longitudinal study. Bone Marrow Transplant 2007; 39:491.</a></li><li><a class="nounderline abstract_t">Bevans M, El-Jawahri A, Tierney DK, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report. Biol Blood Marrow Transplant 2017; 23:538.</a></li><li><a class="nounderline abstract_t">Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica 2017; 102:614.</a></li><li><a class="nounderline abstract_t">Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol 2012; 30:71.</a></li><li><a class="nounderline abstract_t">Majhail NS, Challa TR, Mulrooney DA, et al. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:1100.</a></li><li><a class="nounderline abstract_t">Tichelli A, Passweg J, Wójcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93:1203.</a></li><li><a class="nounderline abstract_t">Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011; 118:6023.</a></li><li><a class="nounderline abstract_t">Chow EJ, Wong K, Lee SJ, et al. Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014; 20:794.</a></li><li><a class="nounderline abstract_t">Armenian SH, Sun CL, Francisco L, et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 2008; 26:5537.</a></li><li><a class="nounderline abstract_t">Chow EJ, Mueller BA, Baker KS, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 2011; 155:21.</a></li><li><a class="nounderline abstract_t">Armenian SH, Sun CL, Vase T, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood 2012; 120:4505.</a></li><li><a class="nounderline abstract_t">Chow EJ, Baker KS, Lee SJ, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 2014; 32:191.</a></li><li><a class="nounderline abstract_t">Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 2010; 116:1197.</a></li><li><a class="nounderline abstract_t">Armenian SH, Sun CL, Mills G, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16:1138.</a></li><li><a class="nounderline abstract_t">Majhail NS, DeFor T, Lazarus HM, Burns LJ. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant 2008; 14:790.</a></li><li><a class="nounderline abstract_t">Majhail NS, DeFor TE, Lazarus HM, Burns LJ. Iron-overload after autologous hematopoietic cell transplantation. Leuk Res 2009; 33:578.</a></li><li><a class="nounderline abstract_t">Rose C, Ernst O, Hecquet B, et al. Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica 2007; 92:850.</a></li><li><a class="nounderline abstract_t">Pullarkat V. Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol 2010; 2010.</a></li><li><a class="nounderline abstract_t">Majhail NS, Lazarus HM, Burns LJ. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 2010; 16:832.</a></li><li><a class="nounderline abstract_t">Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer 2008; 113:1580.</a></li><li><a class="nounderline abstract_t">Ando M, Ohashi K, Akiyama H, et al. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors. Nephrol Dial Transplant 2010; 25:278.</a></li><li><a class="nounderline abstract_t">Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18:348.</a></li><li><a class="nounderline abstract_t">Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007; 109:1765.</a></li><li><a class="nounderline abstract_t">Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009; 43:49.</a></li><li><a class="nounderline abstract_t">Rovó A, Daikeler T, Halter J, et al. Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. Haematologica 2011; 96:150.</a></li><li><a class="nounderline abstract_t">Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood 2009; 113:306.</a></li><li><a class="nounderline abstract_t">Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 2004; 104:1898.</a></li><li><a class="nounderline abstract_t">Molassiotis A, van den Akker OB, Milligan DW, Boughton BJ. Gonadal function and psychosexual adjustment in male long-term survivors of bone marrow transplantation. Bone Marrow Transplant 1995; 16:253.</a></li><li><a class="nounderline abstract_t">Chatterjee R, Andrews HO, McGarrigle HH, et al. Cavernosal arterial insufficiency is a major component of erectile dysfunction in some recipients of high-dose chemotherapy/chemo-radiotherapy for haematological malignancies. Bone Marrow Transplant 2000; 25:1185.</a></li><li><a class="nounderline abstract_t">Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant 2002; 30:447.</a></li><li><a class="nounderline abstract_t">Phelan R, Mann E, Napurski C, et al. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning. Bone Marrow Transplant 2016; 51:1369.</a></li><li><a class="nounderline abstract_t">Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988; 6:813.</a></li><li><a class="nounderline abstract_t">Hammond C, Abrams JR, Syrjala KL. Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls. J Clin Oncol 2007; 25:3511.</a></li><li><a class="nounderline abstract_t">Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006; 12:138.</a></li><li><a class="nounderline abstract_t">McClune BL, Majhail NS. Osteoporosis after stem cell transplantation. Curr Osteoporos Rep 2013; 11:305.</a></li><li><a class="nounderline abstract_t">Pundole XN, Barbo AG, Lin H, et al. Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation. J Clin Oncol 2015; 33:1364.</a></li><li><a class="nounderline abstract_t">Yao S, Smiley SL, West K, et al. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16:1130.</a></li><li><a class="nounderline abstract_t">Le Meignen M, Auquier P, Barlogis V, et al. Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities. Blood 2011; 118:1481.</a></li><li><a class="nounderline abstract_t">McClune B, Majhail NS, Flowers ME. Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Semin Hematol 2012; 49:59.</a></li><li><a class="nounderline abstract_t">Yao S, McCarthy PL, Dunford LM, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant 2008; 41:393.</a></li><li><a class="nounderline abstract_t">Savani BN, Donohue T, Kozanas E, et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:517.</a></li><li><a class="nounderline abstract_t">Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6:165.</a></li><li><a class="nounderline abstract_t">Campbell S, Sun CL, Kurian S, et al. Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. Cancer 2009; 115:4127.</a></li><li><a class="nounderline abstract_t">Treister N, Duncan C, Cutler C, Lehmann L. How we treat oral chronic graft-versus-host disease. Blood 2012; 120:3407.</a></li><li><a class="nounderline abstract_t">Välimäki MJ, Kinnunen K, Volin L, et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999; 23:355.</a></li><li><a class="nounderline abstract_t">Hari P, DeFor TE, Vesole DH, et al. Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19:1361.</a></li><li><a class="nounderline abstract_t">Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med 1990; 89:733.</a></li><li><a class="nounderline abstract_t">Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment. Am J Clin Dermatol 2018; 19:33.</a></li><li><a class="nounderline abstract_t">Majhail NS, Ness KK, Burns LJ, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 2007; 13:1153.</a></li><li><a class="nounderline abstract_t">Elad S, Raber-Durlacher JE, Brennan MT, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer 2015; 23:223.</a></li><li><a class="nounderline abstract_t">Rizzo JD, Curtis RE, Socié G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113:1175.</a></li><li><a class="nounderline abstract_t">Inamoto Y, Petriček I, Burns L, et al. Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2019; 25:e145.</a></li><li><a class="nounderline abstract_t">Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant 2019; 54:662.</a></li><li><a class="nounderline abstract_t">Inamoto Y, Petriček I, Burns L, et al. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant 2019; 54:648.</a></li><li><a class="nounderline abstract_t">Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2019; 25:e46.</a></li><li><a class="nounderline abstract_t">Gurney JG, Ness KK, Rosenthal J, et al. Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study. Cancer 2006; 106:1402.</a></li><li><a class="nounderline abstract_t">Syrjala KL, Dikmen S, Langer SL, et al. Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood 2004; 104:3386.</a></li><li><a class="nounderline abstract_t">Kelly DL, Buchbinder D, Duarte RF, et al. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2018; 24:228.</a></li><li><a class="nounderline abstract_t">Perkins JL, Kunin-Batson AS, Youngren NM, et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer 2007; 49:958.</a></li><li><a class="nounderline abstract_t">Jim HS, Small B, Hartman S, et al. Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation. Cancer 2012; 118:3407.</a></li></ol></div><div id="topicVersionRevision">Topic 122403 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21464398" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20065176" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20656930" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19747641" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671231" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15701723" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20212247" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19573079" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27870568" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28641097" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Long-term complications after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21223255" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18677717" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15170167" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8485479" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198954" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16741851" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Quality of life and psychosocial situation before and after a lung, liver or an allogeneic bone marrow transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16751786" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11071263" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12407437" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15937502" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150205" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3515649" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adaptation of adult bone marrow transplant recipient long-term survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134219" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recovery after stem-cell transplantation for hematologic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981005" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659507" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15777342" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Quality of life in adult hematopoietic cell transplant patients at least 5 yr after treatment: a comparison with healthy controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190995" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660144" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Quality of life, quality of care, and patient satisfaction: perceptions of patients undergoing outpatient autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135938" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549432" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529850" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1638031" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dynamic assessment of quality of life after autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14962235" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19919651" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17438588" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Symptom burden in patients undergoing autologous stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15378094" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fatigue and depression in patients with lymphoma undergoing autologous peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314087" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical factors associated with fatigue in haematologic cancer patients receiving stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032271" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17417661" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1350338" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193757" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Quality of life following bone marrow transplantation: a comparison of patient reports with population norms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15343272" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170167" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17621377" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Psychological distress in long-term survivors of hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17416860" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089962" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21821714" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10997973" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Quality of life in 244 recipients of allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16788100" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15815185" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Quality of life 5 or more years post-autologous hematopoietic stem cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21725373" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10642812" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12673808" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Caregiver and patient marital satisfaction and affect following hematopoietic stem cell transplantation: a prospective, longitudinal investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15765819" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Psychosocial function after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10516705" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23512286" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Increase of suicide and accidental death after hematopoietic stem cell transplantation: a cohort study on behalf of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11956273" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27565521" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27123741" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23319686" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22565413" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Internet-based program for coping with cancer: a randomized controlled trial with hematologic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147646" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : 'Open Window': a randomized trial of the effect of new media art using a virtual window on quality of life in patients' experiencing stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14983763" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sexuality following hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26372459" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sexual health in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17322932" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sexual functioning in patients undergoing bone marrow transplantation: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27660168" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232372" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Late effects of blood and marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147737" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19660723" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18556401" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976673" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565992" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Late cardiovascular complications after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809605" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Late congestive heart failure after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21727290" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23034279" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297944" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439623" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20197101" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541198" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18632150" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Iron-overload after autologous hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17550861" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20871852" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Iron overload in patients undergoing hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20079863" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18704986" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762604" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22178693" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17047152" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18724397" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20851864" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838614" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Thyroid function following hematopoietic cell transplantation in children: 30 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172972" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581144" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Gonadal function and psychosexual adjustment in male long-term survivors of bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10849531" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cavernosal arterial insufficiency is a major component of erectile dysfunction in some recipients of high-dose chemotherapy/chemo-radiotherapy for haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12368957" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27272448" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3130466" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Ovarian function following marrow transplantation for aplastic anemia or leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646668" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443512" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24202854" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Osteoporosis after stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25779562" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20188201" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21596857" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22221785" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17994116" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17448910" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10816024" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Mechanisms of osteoporosis after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19536905" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22898605" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : How we treat oral chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10100579" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806773" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2252042" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28656563" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17889351" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25189149" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971419" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Solid cancers after allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30521975" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30531954" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30531955" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30481594" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16453335" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15251983" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28939455" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17474113" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22139882" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
